Table 1. Background and Clinical Characteristics of Patients and Controls.
| Characteristic | Patients Treated With Chemotherapy(CT) (n =19) |
Healthy Controls (HC)(n=11) |
Paired t-test | P | ||
|---|---|---|---|---|---|---|
| Mean or Count | SD | Mean or Count | SD | |||
| Age | 43.1 | 8.8 | 42.4 | 5.3 | 0.252 | 0.803 |
| Breast cancer stage | ||||||
| I | 6 | N/A | N/A | N/A | N/A | N/A |
| II | 11 | N/A | N/A | N/A | N/A | N/A |
| III | 2 | N/A | N/A | N/A | N/A | N/A |
| Protocol of adjuvant chemotherapy | ||||||
| 3FET-3T | 7 | N/A | N/A | N/A | N/A | N/A |
| 4EC-4T | 7 | N/A | N/A | N/A | N/A | N/A |
| 4TC | 3 | N/A | N/A | N/A | N/A | N/A |
| 6TEC | 2 | N/A | N/A | N/A | N/A | N/A |
| Test duration | 118.6 | 32.2 | 118.7 | 23.8 | -0.013 | 0.990 |
| STAI at baseline | ||||||
| S-AI | 34.7 | 10.3 | 23.5 | 10.0 | -2.93 | 0.007* |
| T-AI | 27.8 | 9.1 | 21.8 | 8.2 | -1.793 | 0.084 |
| Years of education | 13.5 | 3.6 | 12.0 | 2.9 | 1.194 | 0.242 |
| menopause at baseline | 13 | N/A | 7 | N/A | N/A | N/A |
* Statistically significant; N/A: not applicable; SD: standard deviation; 3FET-3T: three cycles fluorouracil, epirubicin and cyclophosphamide +three cycles paclitaxel; 4EC-4T: four cycles epirubicin, and cyclophosphamide +four cycles paclitaxel; 4TC: four cycles docetaxel and cyclophosphamide; STAI: State-Trait Anxiety Inventory; S-AI: State Anxiety Inventory: T-AI: Trait Anxiety Inventory.